EA201891008A3 - Лечение симптомов, связанных с андроген-депривационной терапией - Google Patents

Лечение симптомов, связанных с андроген-депривационной терапией

Info

Publication number
EA201891008A3
EA201891008A3 EA201891008A EA201891008A EA201891008A3 EA 201891008 A3 EA201891008 A3 EA 201891008A3 EA 201891008 A EA201891008 A EA 201891008A EA 201891008 A EA201891008 A EA 201891008A EA 201891008 A3 EA201891008 A3 EA 201891008A3
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
symptoms associated
androgen
deprivation therapy
therapy
Prior art date
Application number
EA201891008A
Other languages
English (en)
Other versions
EA201891008A2 (ru
EA034553B1 (ru
Inventor
Чарльз Томас Бенсон
Ханна Ю
Рейчел Ричей
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201891008A2 publication Critical patent/EA201891008A2/ru
Publication of EA201891008A3 publication Critical patent/EA201891008A3/ru
Publication of EA034553B1 publication Critical patent/EA034553B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Описан способ лечения симптомов, связанных с андроген-депривационной терапией, включающий введение пациенту, нуждающемуся в таком лечении, эффективного количества соединения формулы Iили его фармацевтически приемлемой соли.
EA201891008A 2014-09-11 2015-09-08 Способ получения соединения для лечения симптомов, связанных с антиандрогенной терапией EA034553B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11

Publications (3)

Publication Number Publication Date
EA201891008A2 EA201891008A2 (ru) 2018-09-28
EA201891008A3 true EA201891008A3 (ru) 2019-03-29
EA034553B1 EA034553B1 (ru) 2020-02-19

Family

ID=54151401

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201891008A EA034553B1 (ru) 2014-09-11 2015-09-08 Способ получения соединения для лечения симптомов, связанных с антиандрогенной терапией
EA201790220A EA033606B1 (ru) 2014-09-11 2015-09-08 Лечение симптомов, связанных с андроген-депривационной терапией

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201790220A EA033606B1 (ru) 2014-09-11 2015-09-08 Лечение симптомов, связанных с андроген-депривационной терапией

Country Status (23)

Country Link
US (4) US10758515B2 (ru)
EP (2) EP3191094B1 (ru)
JP (4) JP6893171B2 (ru)
KR (5) KR102024493B1 (ru)
CN (4) CN113651797A (ru)
AP (1) AP2017009795A0 (ru)
AU (2) AU2015315431C1 (ru)
BR (2) BR122018007412B1 (ru)
CA (2) CA3067289C (ru)
EA (2) EA034553B1 (ru)
ES (1) ES2779978T3 (ru)
HK (1) HK1252811A1 (ru)
IL (3) IL279209B2 (ru)
JO (2) JOP20180072A1 (ru)
MA (1) MA45416A (ru)
MX (2) MX2017003140A (ru)
MY (2) MY195767A (ru)
NZ (1) NZ728612A (ru)
SG (2) SG11201701630VA (ru)
TW (1) TWI616201B (ru)
UA (1) UA120099C2 (ru)
WO (1) WO2016040234A1 (ru)
ZA (1) ZA201802680B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
JP2023511612A (ja) 2020-01-27 2023-03-20 エイルゲン ファーマ リミテッド 腎臓疾患の治療のためのテトラヒドロシクロペンタ［ｂ］インドール化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4603528B2 (ja) * 2003-01-13 2010-12-22 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体の大規模合成
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
AR060974A1 (es) 2006-05-31 2008-07-23 Glaxo Group Ltd Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior
US20090156614A1 (en) * 2006-07-19 2009-06-18 Dalton James T Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
CA2724629C (en) * 2008-05-16 2014-08-19 Eli Lilly And Company Tetrahydrocyclopenta[b]indole androgen receptor modulators
US8003689B2 (en) * 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) * 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
PT2915804T (pt) 2012-10-31 2019-06-06 Fujifilm Corp Novos derivados de amina ou os seus sais como inibidores do fnt alfa
ES2809535T3 (es) * 2013-12-09 2021-03-04 UCB Biopharma SRL Derivados de imidazopiridina como moduladores de la actividad de TNF
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Also Published As

Publication number Publication date
KR20170040338A (ko) 2017-04-12
IL250291A0 (en) 2017-03-30
IL258651A (en) 2018-06-28
JP2017527584A (ja) 2017-09-21
US10799478B2 (en) 2020-10-13
EA201891008A2 (ru) 2018-09-28
BR122018007412B1 (pt) 2022-08-23
CA3067289A1 (en) 2016-03-17
JP2019089795A (ja) 2019-06-13
JP6938550B2 (ja) 2021-09-22
KR102024493B1 (ko) 2019-09-23
AU2015315431B2 (en) 2018-03-08
JP6893171B2 (ja) 2021-06-23
IL258651B (en) 2021-02-28
EP3191094A1 (en) 2017-07-19
AU2018202714A1 (en) 2018-05-17
CA2956514A1 (en) 2016-03-17
EP3375444A1 (en) 2018-09-19
MX2017003140A (es) 2017-05-23
WO2016040234A1 (en) 2016-03-17
AU2018202714B2 (en) 2019-06-20
JOP20180072A1 (ar) 2019-01-30
JP2022000432A (ja) 2022-01-04
CA2956514C (en) 2023-04-18
EA034553B1 (ru) 2020-02-19
US20240148694A1 (en) 2024-05-09
EA033606B1 (ru) 2019-11-08
MY198753A (en) 2023-09-23
JP2023145479A (ja) 2023-10-11
JO3609B1 (ar) 2020-08-27
IL279209B (en) 2022-10-01
US20200390744A1 (en) 2020-12-17
CA3067289C (en) 2023-04-04
TWI616201B (zh) 2018-03-01
MY195767A (en) 2023-02-10
MX2021014120A (es) 2022-01-04
CN113521068A (zh) 2021-10-22
ZA201802680B (en) 2020-08-26
EA201790220A1 (ru) 2017-07-31
IL279209B2 (en) 2023-02-01
UA120099C2 (uk) 2019-10-10
NZ728612A (en) 2018-03-23
CN108440497A (zh) 2018-08-24
KR20220132669A (ko) 2022-09-30
MA45416A (fr) 2019-04-24
US20170172992A1 (en) 2017-06-22
JP7349480B2 (ja) 2023-09-22
IL250291B (en) 2020-09-30
SG10201809673RA (en) 2018-12-28
BR112017002449B1 (pt) 2022-08-09
IL279209A (en) 2021-01-31
KR20180041268A (ko) 2018-04-23
SG11201701630VA (en) 2017-03-30
HK1252811A1 (zh) 2019-06-06
CN106794178A (zh) 2017-05-31
CN113651797A (zh) 2021-11-16
AU2015315431C1 (en) 2018-08-02
KR20210083370A (ko) 2021-07-06
EP3191094B1 (en) 2020-02-19
ES2779978T3 (es) 2020-08-21
KR20190015628A (ko) 2019-02-13
TW201618782A (zh) 2016-06-01
AP2017009795A0 (en) 2017-03-31
US20190111039A1 (en) 2019-04-18
BR112017002449A2 (pt) 2017-12-05
AU2015315431A1 (en) 2017-03-09
US10758515B2 (en) 2020-09-01
KR102619415B1 (ko) 2024-01-02

Similar Documents

Publication Publication Date Title
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
PH12015501920B1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
PH12017500493A1 (en) Combination therapy
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
PH12016502352A1 (en) Pharmaceutical composition
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
TW201613578A (en) Pharmaceutical combinations
EA201491500A1 (ru) Способы лечения фиброза
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX357763B (es) Tratamiento para cancer pancreatico.
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX2018001684A (es) Metodo de curacion de heridas.
AR099416A1 (es) Terapia combinada para la hipertensión resistente
EA202193276A1 (ru) Способы лечения холангиокарциномы
EA201690214A1 (ru) Способ лечения гипертрофической кардиомиопатии
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
EA202090336A1 (ru) Соединения, их соли и способы лечения заболеваний
UA104030U (ru) Способ лечения больных с обострением хронического бронхита вирусной этиологии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): RU